Annual Report 2023

MANAGEMENT DISCUSSION AND ANALYSIS 10 The United Laboratories International Holdings Limited Annual Report 2023 BUSINESS REVIEW AND FINANCIAL RESULTS For the year ended 31 December 2023, the Group recorded revenue of approximately RMB13,739.9 million, an increase of approximately 21.2% as compared with last year. EBITDA was approximately RMB3,976.7 million, representing a year-on-year increase of 50.6%. Profit attributable to owners of the Company was RMB2,701.4 million, representing a year-on-year increase of 70.9%. Earnings per share were RMB148.67 cents. The Board recommended the payment of a final dividend of RMB28 cents per share and a special dividend of RMB12 cents per share for the year ended 31 December 2023. Together with the interim dividend of RMB12 cents per share already paid, the total dividend for the year was RMB52 cents per share. During the year, segmental revenue (including inter-segment sales) of intermediate products, bulk medicine and finished products increased by 33.2%, 22.3% and 10.2% respectively as compared with last year. Segmental result of intermediate products and bulk medicine increased by 116.0% and 102.7% respectively as compared with last year. Segmental result of finished products decreased by 26.1% as compared with last year. Mr. Leung Wing Hon Vice-Chairman